Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement January 7, 2025
BeiGene to acquire global development, manufacturing, and commercialization rights for an ADC from DualityBio January 7, 2025
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849 Targeting SCLC and NET Solid Tumors December 31, 2024
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia December 31, 2024
Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform December 26, 2024
Marker Therapeutics Awarded $9.5 Million Grant from the CPRIT to Support the Investigation of MT-601 in Patients with Pancreatic Cancer December 26, 2024
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics December 26, 2024
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement December 26, 2024
Merck Closes Exclusive Global License Agreement for Anti-PD-1/VEGF Bispecific Antibody LM-299 December 26, 2024
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on PYX-201 program December 26, 2024
Elevation Oncology Expands Pipeline with Nomination of EO-1022 for the Treatment of HER3-expressing Solid Tumors December 18, 2024
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development December 18, 2024
TC BioPharm Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for PK Monitoring of Allogeneic Cell Therapy December 12, 2024
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors December 10, 2024
Relay Therapeutics & Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors December 10, 2024
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials December 10, 2024
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target December 10, 2024
Olema Oncology Announces New CTA and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement December 4, 2024
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer December 4, 2024
Successful Completion of $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline December 4, 2024
Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio December 4, 2024
